- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of November 5
The Center for Biosimilars® recaps the top news for the week of November 5, 2018.
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of November 5.
Number 5: Oncobiologics has announced that it has dosed the first patients with wet age-related macular degeneration in a clinical trial of ONS-5010, an ophthalmic bevacizumab candidate.
Number 4: Three attorneys from Goodwin hosted a webinar this week to provide updates on topics ranging from the Biologics Price Competition and Innovation Act Litigation, the Patent Trial and Appeal Board, and recent regulatory and FDA issues related to biosimilars.
Number 3: Regeneron posted positive third quarter earnings results for 2018 that show aflibercept sales in the United States increased 7 percent to 1.02 billion dollars versus third quarter 2017 results.
Number 2: Momenta Pharmaceuticals recently announced that it has reached a settlement with Humira-maker AbbVie over a proposed biosimilar adalimumab, M923.
Number 1: Sandoz announced this week that it will no longer pursue FDA approval for its biosimilar rituximab, GP2013.
Finally, last week, our e-newsletter asked if the eventual approval of upadacitinib could curb the uptake of biosimilar infliximab.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
